3-(3-fluorophenyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one | 1047655-91-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 英文名称: 3-(3-fluorophenyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one
• CAS: 1047655-91-3
• 化学式: C₁₃H₁₅FN₂O₂
• 分子量: 250.273
• InChiKey: CHJIZJMFNIVWLC-UHFFFAOYSA-N

物化性质

• 沸点：
  379.3±42.0 °C(Predicted)
• 密度：
  1.31±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  、 3-chloro-6-(3-methyl-1,2,4-oxadiazol-5-yl)pyridazine 、 3-(3-fluorophenyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 、 potassium carbonate 生成 3-(3-fluorophenyl)-8-[6-(3-methyl-1,2,4-oxadiazol-5-yl)pyridazin-3-yl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one
  参考文献：
  名称：

  SPIRO COMPOUND AND USE THEREOF

  摘要：

  本发明旨在提供一种新型SCD抑制剂。本发明涉及一种包括式(I)所表示的化合物的SCD抑制剂，其中R是可选取的取代环基或可选取的取代的氨基甲酰基基团，但R不是可选取的取代的7-吡啶并[2,3-d]嘧啶基团；环A是可选取的进一步取代的吡啶并嗪环；R1、R2、R3、R4、R11、R12、R13和R14各自独立地是氢原子或取代基，或者R1和R11组合、R2和R12组合、R3和R13组合或R4和R14组合可选地形成氧代基，或R2和R4组合可选地形成键或烷基交联；m和n各自独立地是0到2的整数；环B是可选取的取代环，但构成环B的两个相邻的螺旋碳原子不同时为氧原子，或其盐或前药。

  公开号：

  US20100069351A1

文献信息

• Spiro compounds having stearoyl-CoA desaturase action
  申请人：Taniguchi Takahiko

  公开号：US08575167B2

  公开（公告）日：2013-11-05

  The present invention aims to provide a novel SCD inhibitor. The present invention relate to SCD inhibitor comprising A compound represented by the formula (I) wherein R is an optionally substituted cyclic group or an optionally substituted carbamoyl group, provided that R is not an optionally substituted 7-pyrido[2,3-d]pyrimidyl group; ring A is an optionally further substituted pyridazine ring; R1, R2, R3, R4, R11, R12, R13 and R14 are each independently a hydrogen atom or a substituent, or R1 and R11 in combination, R2 and R12 in combination, R3 and R13 in combination, or R4 and R14 in combination optionally form an oxo group, or R2 and R4 in combination optionally form a bond or an alkylene cross-linkage; m and n are each independently an integer of 0 to 2; ring B is an optionally substituted ring, provided that the two atoms constituting ring B, which are adjacent to the spiro carbon atom, are not oxygen atoms at the same time, or a salt thereof, or a prodrug thereof.

  本发明旨在提供一种新型SCD抑制剂。本发明涉及一种包括式(I)所表示的化合物的SCD抑制剂，其中R是一个可选取的取代环基团或可选取的取代的氨基甲酰基基团，但R不能是一个可选取的取代的7-吡啶并[2,3-d]嘧啶基团；环A是一个可选取的进一步取代的吡啶并咪唑环；R1、R2、R3、R4、R11、R12、R13和R14各自独立地是氢原子或取代基，或者R1和R11组合、R2和R12组合、R3和R13组合、或R4和R14组合可以选择形成一个氧代基，或R2和R4组合可以选择形成一个键或一个烷基交联；m和n各自独立地是0到2的整数；环B是一个可选取的取代环，但构成环B的两个相邻于螺碳原子的原子不同时为氧原子；或其盐或前药。
• Novel Piperidine Derivative
  申请人：Ishikawa Shiho

  公开号：US20090137576A1

  公开（公告）日：2009-05-28

  Disclosed is a substance having an antagonistic effect on the binding of histamine to a histamine H3 receptor or an inhibitory effect on the activity which a histamine H3 receptor constantly exhibits. A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof; (I) wherein R1 represents a phenyl group which may be substituted or the like and R2 represents a cyano group which may be substituted or the like, or R1 and R2 together form an aliphatic heterocylic ring which may be substituted; R3 represents a group represented by the formula (II-1) below; and all of X1 to X4 represent a carbon atom or the like: (II-1) where R4 and R5 represent a lower alkyl group or the like; and m1 represents an integer of 2 to 4.

  本发明涉及一种物质，其对组胺与组胺H3受体的结合具有拮抗作用，或对组胺H3受体不断表现的活性具有抑制作用。化合物由式(I)或其药学上可接受的盐表示；(I)其中R1代表可能被取代或类似的苯基团，R2代表可能被取代或类似的氰基团，或R1和R2一起形成可能被取代的脂肪族杂环环；R3代表由下式(II-1)表示的基团；X1到X4都表示碳原子或类似物：(II-1)其中R4和R5代表较低的烷基团或类似物；m1表示2到4的整数。
• NOVEL PIPERIDINE DERIVATIVE
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1892241A1

  公开（公告）日：2008-02-27

  Disclosed is a substance having an antagonistic effect on the binding of histamine to a histamine H3 receptor or an inhibitory effect on the activity which a histamine H3 receptor constantly exhibits. A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof; (I) wherein R1 represents a phenyl group which may be substituted or the like and R2 represents a cyano group which may be substituted or the like, or R1 and R2 together form an aliphatic heterocylic ring which may be substituted; R3 represents a group represented by the formula (II-1) below; and all of X1 to X4 represent a carbon atom or the like: (II-1) where R4 and R5 represent a lower alkyl group or the like; and ml represents an integer of 2 to 4.

  本发明公开了一种对组胺与组胺 H3 受体的结合具有拮抗作用或对组胺 H3 受体持续表现出的活性具有抑制作用的物质。由式(I)代表的化合物或其药学上可接受的盐； (I) 其中 R1 代表可被取代的苯基或类似基团，R2 代表可被取代的氰基或类似基团，或 R1 和 R2 共同形成可被取代的脂族杂环；R3 代表下式(II-1)所代表的基团； 且所有 X1 至 X4 均代表碳原子或类似物：(II-1) 其中 R4 和 R5 代表低级烷基或类似基团；ml 代表 2 至 4 的整数。
• US8138206B2
  申请人：——

  公开号：US8138206B2

  公开（公告）日：2012-03-20
• US8575167B2
  申请人：——

  公开号：US8575167B2

  公开（公告）日：2013-11-05